Ascelia Pharma AB (publ) (STO:ACE)

Market Cap	474.54M
Revenue (ttm)	n/a
Net Income (ttm)	-85.07M
Shares Out	116.03M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	38.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,436,814
Average Volume	1,011,482
Open	4.265
Previous Close	4.220
Day's Range	4.000 - 4.315
52-Week Range	2.000 - 11.680
Beta	0.99
RSI	66.52
Earnings Date	May 16, 2025

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology. Ascelia Ph...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE